ClinicalTrials.gg
CompletedNCT03298893NiCOLUpdated Sep 19, 2025

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

A Phase 1/2 interventional study of Nivolumab Injection and Cisplatin in Cervical Cancer and Locally Advanced Cervical Cancer, sponsored by Institut Curie. Completed at 3 sites in France. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Institut Curie · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nivolumab in Uterine Cervical Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Nivolumab · Uterine Cervical Neoplasms.

Enrollment
10th of 14
21 · median 33
Started
2017
with 1 other
Phase 1/2
Only one
of the 14
Registered
4th of 14
by date
Lead sponsor
1 of 14
Institut Curie

Among the 14 studies testing nivolumab in Uterine Cervical Neoplasms, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 1/2, and was the 4th registered.

Uterine Cervical Neoplasms

2,366 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 14 studies testing nivolumab in Uterine Cervical Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nivolumab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

To date, the majority of clinical trials on checkpoint inhibitors have tested these agents as monotherapy, and the next logical step is to evaluate rational therapeutic associations. The aim of the NiCOL study is to assess the safety of nivolumab in association with chemoradiation therapy and to gain initial insight into its efficacy in association with the current standard of care, including chemoradiation.

03

Conditions studied

  • Cervical Cancer
  • Locally Advanced Cervical Cancer

Keywords

  • cervical cancer
  • nivolumab
  • cisplatin
  • radiotherapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients at least 18 years of age;
  2. Ability to understand and the willingness to sign a written document.;
  3. (ECOG) Performance Status 0 or 1;
  4. confirmed locally advanced cervical cancer, i.e. FIGO stages IB2 to IVA, squamous-cell carcinoma or adenocarcinoma, with indication for radiotherapy and cisplatin-based chemotherapy with a curative intent as confirmed by a multidisciplinary board including a radiation oncologist. expression on tumor will not be required for inclusion; (staging may include [18F]-fluorodeoxyglucose (FDG) PET-CT and/or para-aortic dissection in accordance with usual practice in each center and at the Investigator's discretion);
  5. Disease amenable to since three tumor samples are mandatory prior to treatment;
  6. Laboratory values at Screening must meet the following criteria :

    neutrophils ≥ 1.0 x 109/L, lymphocytes ≥ 0.5 x 109/L, ≥ 100 x 109/L, ≥ 8.0 g/dL, creatinine ≤ 2 times the (ULN), (AST) ≤ 3 ULN, alanine aminotransferase (ALT) ≤ 3 x ULN, total ≤ 1.5 x ULN (≤ 3 x ULN if genetically documented Gilbert's syndrome).

  7. For women with , negative blood or urinary pregnancy test within 24 hours of initiation of nivolumab, as well as appropriate method of throughout the study ;
  8. Affiliated to the French Social Security System.

Exclusion criteria

Exclusion Criteria:

  1. (except pelvic and/or para-aortic nodal metastases) ;
  2. Peritoneal carcinosis;
  3. Sensory or motor neuropathy ≥ grade 2;
  4. Active or recent history of known disease or recent history of a syndrome that required systemic or drugs, except for :

    • hydrocortisone, which is permitted at physiological doses;
    • syndromes that would not be expected to recur in the absence of an external trigger, e.g. glomerulonephritis;
    • vitiligo or autoimmune thyroiditis;
  5. Type-1 or type-2 diabetes;
  6. History of or current immunodeficiency disease, including known history of infection with ;
  7. Prior systemic treatment or radiotherapy for cervical cancer;
  8. Prior stem cell transplantation;
  9. Prior immunotherapy, including tumor vaccine, cytokine, anti-CTLA4, , anti-PD-L1 or similar agents;
  10. Any non-oncologic vaccine for prevention of infectious disease within 28 days prior to inclusion, including but not limited to measles, mumps, rubella, chicken pox, yellow fever, seasonal influenza, H1N1, rabies, BCG, and typhoid vaccine;
  11. Positive serology for surface antigen;
  12. Positive for hepatitis-C ribonucleic acid on polymerase chain reaction;
  13. Active infection requiring therapy;
  14. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT-scan at Screening;
  15. History of (excepting non-melanoma skin cancer) unless complete remission was achieved at least 3 years prior to inclusion and no additional therapy is required or planned during the study;
  16. Underlying medical condition that, in the Investigator's opinion, could render the administration of the study treatment hazardous; additional severe and/or uncontrolled concurrent disease;
  17. Concomitant use of other drugs;
  18. Pregnancy or breastfeeding.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Nivolumab + radiochemotherapy

    5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone

    Drug: Nivolumab Injection · Drug: Cisplatin · Radiation: radiotherapy

Interventions

  • 2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks

  • 40 mg/m2, once a week during radiotherapy

  • Radiationradiotherapy

    Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy. An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT. An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center.

06

What researchers measure

Primary outcomes

  1. rate of occurrence of dose-limiting toxicity (DLT)

    DLT is defined as any of the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0: * non-hematological toxicity ≥ grade 3; * immune-related adverse event ≥ grade 3; * symptomatic immune-related adverse event ≥ grade 2 resistant to optimal supportive care for \> 7 days; * dosing delay in RT ≥ 1 week due to toxicity related to nivolumab, chemotherapy or RT; * colitis or diarrhea ≥ grade 3.

    Time frame: within 11 weeks after the initiation of treatment.

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of all subjects whose best response is either a complete response or a partial response.

    Time frame: after the end of RT and before brachytherapy and again up to 2 months after brachytherapy

  2. Progression Free Survival (PFS)

    PFS is defined as the length of time from the start of treatment to disease progression or death, regardless of the cause of death

    Time frame: 2 years

  3. Disease Free Survival (DFS)

    DFS is defined as the length of time from the start of complete response to the time of relapse from complete response. DFS applies only to patients in complete response.

    Time frame: 2 years

  4. Incidence of Serious Adverse Events (SAEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy

    Time frame: from the first intake of the IMP until 100 days after the last intake of the IMP

  5. Incidence of Adverse Events (AEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy

    Time frame: from the first intake of the IMP until 100 days after the last intake of the IMP

  6. validation of molecular alterations detected by molecular analyses

    Retrospective exome, RNA and targeted sequencing analyses will be performed on all patients treated and for whom tumor samples are available.

    Time frame: 2 years

  7. ctDNA heterogeneity

    Retrospective exome and targeted sequencing analyses will be performed on all patients treated and for whom tissue samples are available at the different timepoints

    Time frame: baseline, at Weeks 3, 6 and 12 and every 12 weeks up to Week 104

  8. tumor microenvironment description

    phenotypic analysis of the different components of the tumor microenvironment using various technologies

    Time frame: 2 years

  9. tumor PD-L1 immunohistochemistry

    Time frame: 2 years

07

Study locations

3 sites
  • Institut Curie
    Paris, 75005, France
  • Hopital Européen Georges Pompidou
    Paris, 75015, France
  • Institut Curie Hopital René Huguenin
    Saint-Cloud, 9220, France
08

References and documents

Publications

  • Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, Bazire L, Durdux C, Fourchotte V, Laas E, Pouget N, Castel-Ajgal Z, Marret G, Lesage L, Meseure D, Vincent-Salomon A, Lecompte L, Servant N, Vacher S, Bieche I, Malhaire C, Huchet V, Champion L, Kamal M, Amigorena S, Lantz O, Chevrier M, Romano E. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun. 2023 Jun 22;14(1):3698. doi: 10.1038/s41467-023-39383-8. PubMed 37349318 ↗

Individual participant data

Plan to share: Yes — Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2020, 35 months.

Of 81 phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 75. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 2, 2017
StartActual
Nov 27, 2017
Primary completionActual
Oct 30, 2020
CompletionActual
Mar 7, 2022
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03298893
Lead sponsor
Institut Curie
Responsible party
Sponsor
First posted
Oct 2, 2017
Start date
Nov 27, 2017
Primary completion
Oct 30, 2020
Completion
Mar 7, 2022
Last update
Sep 19, 2025

Study contacts

Emanuela Romano, MD
study director · Institut Curie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cisplatin

Start the discussion